Jubilant Ingrevia Limited has informed stock exchanges about receiving a GST demand order from tax authorities for Service Tax on Ocean Freight for the financial year 2017-18. The disclosure was made on February 9, 2026, pursuant to Regulation 30 of the SEBI Listing Regulations.

GST Demand Order Details

The Assistant Commissioner, Central Goods & Service Tax, Bijnor has confirmed the demand for Service Tax on Ocean Freight with the following components:

The demand has been raised under Section 73(1) of the Finance Act, 1994 read with Section 142 and Section 174 of the CGST Act, 2017.

Company's Response and Legal Action

Jubilant Ingrevia has indicated it will contest the demand order through proper legal channels. The company plans to file an appeal before the Commissioner (Appeals) against the impugned demand order after receiving the signed or certified copy of the order from the GST authorities.

Financial Impact Assessment

The company has assessed that there will be no material financial or operational impact from this demand order. Management believes it has a strong case to defend on merits and is confident in its legal position regarding the Service Tax demand on Ocean Freight.

Regulatory Compliance

The disclosure was made in compliance with SEBI regulations, specifically under Regulation 30 of the Listing Regulations read with Schedule III and the SEBI Master Circular. The company has also posted the relevant documents on its website at www.jubilantingrevia.com as part of its transparency obligations to stakeholders.

Jubilant Ingrevia Limited has released the transcript of its Q3FY26 earnings conference call held on February 05, 2026, providing comprehensive insights into the company's financial performance and operational outlook. The specialty chemicals and pharmaceutical intermediates company faced margin compression across all business segments despite stable revenue performance.

Q3FY26 Financial Performance Overview

The company's consolidated results for Q3FY26 demonstrate comprehensive margin compression across all business segments. While revenue remained relatively stable, both EBITDA and net profit experienced significant declines compared to the corresponding quarter of the previous year.

Segment-wise Performance Analysis

The company's three business segments showed mixed performance during Q3FY26, with pricing pressures affecting profitability across all divisions despite volume improvements in several areas.

Specialty Chemicals Segment

The Specialty Chemicals segment reported revenue of ₹458 crore compared to ₹468 crore in Q3FY25, representing a 2% decline. EBITDA for this segment decreased to ₹116 crore from ₹121 crore year-on-year, though it maintained a healthy margin of 25%. The segment continued to show strong volume growth in Pyridine & Derivatives portfolio but faced pricing pressures across core products.

Nutrition & Health Solutions Segment

Nutrition & Health Solutions achieved revenue growth of 6% year-on-year to ₹201 crore from ₹190 crore in Q3FY25. However, EBITDA declined to ₹23 crore from ₹25 crore, with margins compressing to 11% from 13%. The segment recorded its highest B3 vitamin volumes in the last seven quarters, though pricing remained under pressure due to global supply-demand imbalances.

Chemical Intermediates Segment

The Chemical Intermediates segment faced the most significant challenges, with revenue declining 2% to ₹393 crore from ₹400 crore year-on-year. EBITDA fell substantially to ₹15 crore from ₹22 crore, representing a 31% decrease. The segment maintained market share and achieved volume growth but was severely impacted by pricing pressures across key products.

Management Commentary on Market Conditions

During the earnings call, CEO and Managing Director Deepak Jain acknowledged the challenging market environment, stating that pricing pressures have bottomed out across most segments. The company has already witnessed some price uptick in certain derivatives, with vitamin B3 feed grade prices increasing by 7-8% in recent days. Management expressed confidence that the worst of the pricing decline is behind them.

CDMO Business and Growth Pipeline

The company continues to make significant progress in its CDMO business, with over 100 active opportunities representing a peak annual revenue potential of ₹3,500 crore. During the fiscal year, Jubilant Ingrevia has secured confirmation for 16 molecules with an estimated peak potential of ₹1,400 crore, up from ₹1,200 crore in the previous quarter.

Nine-Month Performance and Outlook

For the nine-month period of FY26, the company demonstrated resilience with revenue growing 3% to ₹3,210 crore and EBITDA increasing 8% to ₹436 crore. Net profit for the nine-month period grew 8% to ₹191 crore, indicating stronger performance in earlier quarters. The company has recommended an interim dividend of 250%, translating to ₹2.50 per equity share.

Looking ahead to Q4 FY26, management expects sustained growth momentum driven by progress in Specialty Chemicals and Nutrition businesses, alongside a partial recovery in the acetyls portfolio. The company anticipates that full-year FY26 EBITDA will exceed the 8% increase already achieved in the first nine months.

Major CDMO Project Commissioning

The company remains on track to commence delivery of its major CDMO order in March 2026. The agrochemical intermediate project at Bharuch has been successfully commissioned, with the first batch already charged. Management confirmed that the plant is ready and expects to start dispatching volumes by mid to late March, marking a significant milestone in the company's CDMO journey.

Source: Jubilant Ingrevia Limited earnings call transcript for Q3FY26 results held on February 05, 2026